Co Diagnostics Inc (CODX) Share Price

Mar 3 short volumes: CODX 34%, FLGT 69%, QDEL 54%, VERU 56%.

Feb 28 short volumes: CODX 22%, FLGT 56%, QDEL 57%, VERU 67%.

Feb 27 short volumes: CODX 25%, FLGT 42%, QDEL 63%, VERU 58%.

Feb 26 short volumes: CODX 24%, FLGT 68%, QDEL 87%, VERU 63%.

Feb 25 short volumes: CODX 14%, FLGT 64%, QDEL 87%, VERU 46%.

Feb 24 short volumes: CODX 44%, FLGT 62%, QDEL 88%, VERU 55%

Feb 21 short volumes: CODX 49%, FLGT 63%, QDEL 78%, VERU 54%.

Feb 20 short volumes: CODX 24%, FLGT 55%, QDEL 75%, VERU 69%.

Feb 19 short volumes: CODX 17%, FLGT 59%, QDEL 78%, VERU 71%.

Feb 18 short volumes: CODX 43%, FLGT 52%, QDEL 64%, VERU 55%.

Feb 14 short volumes: CODX 9%, FLGT 50%, QDEL 69%, VERU 48%.

Feb 13 short volumes: CODX 10%, FLGT 41%, QDEL 56%, VERU 58%.

Feb 12 short volumes: CODX 12%, FLGT 65%, QDEL 70%, VERU 65%.

Feb 11 short volumes: CODX 10%, FLGT 68%, QDEL 84%, VERU 68%.

Feb 10 short volumes: CODX 25%, FLGT 47%, QDEL 73%, VERU 46%.

Feb 7 short volumes: CODX 15%, FLGT 72%, QDEL 74%, VERU 59%.

Feb 6 short volumes: CODX 20%, FLGT 65%, QDEL 62%, VERU 54%.

Feb 5 short volumes: CODX 16%, FLGT 50%, QDEL 73%, VERU 61%.

Feb 4 short volumes: CODX 4%, FLGT 41%, QDEL 62%, VERU 75%.

Feb 3 short volumes: CODX 51%, FLGT 62%, QDEL 59%, VERU 57%.

Jan 31 short volumes: CODX 13%, FLGT 57%, QDEL 56%, VERU 45%.

Jan 30 short volumes: CODX 5%, FLGT 46%, QDEL 31%, VERU 52%.

Jan 29 short volumes: CODX 25%, FLGT 56%, QDEL 53%, VERU 59%.

Jan 28 short volumes: CODX 18%, FLGT 33%, QDEL 64%, VERU 66%.

Jan 27 short volumes: CODX 34%, FLGT 52%, QDEL 65%, VERU 68%.

Jan 24 short volumes: CODX 19%, FLGT 48%, QDEL 43%, VERU 59%.

Jan 23 short volumes: CODX 41%, FLGT 52%, QDEL 56%, VERU 42%.

Jan 22 short volumes: CODX 12%, FLGT 33%, QDEL 49%, VERU 45%.

Jan 21 short volumes: CODX 17%, FLGT 29%, QDEL 47%, VERU 45%.

Jan 17 short volumes: CODX 19%, FLGT 46%, QDEL 65%, VERU 34%.

Jan 16 short volumes: CODX 35%, FLGT 50%, QDEL 59%, VERU 31%.

Jan 15 short volumes: CODX 19%, FLGT 35%, QDEL 33%, VERU 30%.

Jan 14 short volumes: CODX 21%, FLGT 43%, QDEL 36%, VERU 42%.

Jan 13 short volumes: CODX 9%, FLGT 57%, QDEL 45%, VERU 35%.

CODX...............................https://stockcharts.com/h-sc/ui?s=CODX&p=W&b=5&g=0&id=p86431144783

Jan 10 short volumes: CODX 9%, FLGT 54%, QDEL 41%, VERU 26%.

CODX...83...Adding here...🥳...

georgie18

Member Level
Re: georgie18 post# 4136

Monday, January 06, 2025 1:20:30 PM

Post#
4137
of 4140
CODX...$1.07...on the Breakout...🥳Off my .78 Alert...

georgie18

Member Level
Re: georgie18 post# 670539

Monday, January 06, 2025 1:15:05 PM

Post#
670570
of 670573
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

Jan 8 short volumes: CODX 22%, FLGT 32%, QDEL 49%, VERU 47%.

Jan 7 short volumes: CODX 22%, FLGT 43%, QDEL 66%, VERU 41%.

Jan 6 short volumes: CODX 32%, FLGT 34%, QDEL 52%, VERU 42%.

CODX...$1.07...on the Breakout...🥳Off my .78 Alert...

georgie18

Member Level
Re: georgie18 post# 670539

Monday, January 06, 2025 1:15:05 PM

Post#
670570
of 670573
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

Jan 3 short volumes: CODX 47%, FLGT 34%, QDEL 61%, VERU 33%.

Jan 2 short volumes: CODX 30%, FLGT 34%, QDEL 61%, VERU 39%.

Dec 31 short volumes: CODX 35%, FLGT 33%, QDEL 56%, VERU 52%.

Dec 30 short volumes: CODX 59%, FLGT 47%, QDEL 70%, VERU 56%.

Dec 27 short volumes: CODX 28%, FLGT 37%, QDEL 48%, VERU 43%.

Dec 26 short volumes: CODX 23%, FLGT 33%, QDEL 55%, VERU 48%.